Thomas Todaro, MD, JD, FACC, Medpace Vice President, Medical Affairs.
Over the past several years a number of non-antiarrhythmic drugs
have been withdrawn from the market, or have had their product labels
revised due to the unexpected post-marketing reports of sudden cardiac deaths associated
with a prolongation of the QT interval and the development of Torsade de Pointes (TdP).
In this podcast, Dr. Todaro discusses:
- An overview of thorough QT assessment and its role in early phase drug development for non-antiarrythmic drugs
- Factors to consider in drug development for this class of drug
- Regulatory updates and a forward look at early phase development for cardiac therapeutics
Want to learn more? Contact us.